Dimensional Fund Advisors
CRNX

Dimensional Fund Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Dimensional Fund Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.5M Buy
1,270,531
+418,273
+49% +$15.5M 0.01% 1618
2026
Q1 		$30.9M Buy
852,258
+303,281
+55% +$13.5M 0.01% 1755
2025
Q4 		$25.6M Buy
548,977
+171,175
+45% +$7.62M 0.01% 1859
2025
Q3 		$15.7M Buy
377,802
+202,545
+116% +$6.48M ﹤0.01% 2117
2025
Q2 		$5.04M Buy
175,257
+155,534
+789% +$4.8M ﹤0.01% 2518
2025
Q1 		$662K Buy
+19,723
New +$737K ﹤0.01% 2961
2024
Q4 		– Sell
-392,196
Closed -$20M – 3347
2024
Q3 		$20M Sell
392,196
-154,563
-28% -$7.97M ﹤0.01% 1998
2024
Q2 		$24.5M Sell
546,759
-94,043
-15% -$4.34M 0.01% 1867
2024
Q1 		$30M Sell
640,802
-19,119
-3% -$748K 0.01% 1776
2023
Q4 		$23.5M Sell
659,921
-84,895
-11% -$2.6M 0.01% 1905
2023
Q3 		$22.2M Buy
744,816
+225,707
+43% +$4.65M 0.01% 1867
2023
Q2 		$9.35M Buy
519,109
+69,504
+15% +$1.39M ﹤0.01% 2290
2023
Q1 		$7.22M Buy
+449,605
New +$8.32M ﹤0.01% 2355
2022
Q3 		$10.5M Sell
536,070
-17,801
-3% -$363K ﹤0.01% 2135
2022
Q2 		$10.3M Buy
553,871
+64,514
+13% +$1.29M ﹤0.01% 2176
2022
Q1 		$10.7M Buy
489,357
+143,913
+42% +$2.91M ﹤0.01% 2266
2021
Q4 		$9.81M Buy
345,444
+34,100
+11% +$841K ﹤0.01% 2317
2021
Q3 		$6.55M Buy
311,344
+126,051
+68% +$2.64M ﹤0.01% 2497
2021
Q2 		$3.49M Buy
185,293
+119,573
+182% +$2.1M ﹤0.01% 2710
2021
Q1 		$1M Buy
65,720
+41,825
+175% +$648K ﹤0.01% 3017
2020
Q4 		$337K Buy
+23,895
New +$333K ﹤0.01% 3159

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors's CRNX Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Crinetics Pharmaceuticals (CRNX) stake by 49% in Q2 2026, buying an estimated $15.5M and bringing the position to 1,270,531 shares worth $47.5M. The position accounts for 0.01% of the portfolio, ranked #1618.

Dimensional Fund Advisors first reported a position in CRNX in Q4 2020 and has held it in 21 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Dimensional Fund Advisors held 1,270,531 shares of Crinetics Pharmaceuticals worth $47.5M as of Q2 2026.
  • Dimensional Fund Advisors bought 418,273 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $15.5M.
  • Crinetics Pharmaceuticals made up 0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #1618 holding.
  • Dimensional Fund Advisors first reported a position in Crinetics Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.